People: Anika Therapeutics Inc (ANIK.O)
ANIK.O on Nasdaq
14.18USD
24 May 2013
14.18USD
24 May 2013
Price Change (% chg)
$0.15 (+1.07%)
$0.15 (+1.07%)
Prev Close
$14.03
$14.03
Open
$14.04
$14.04
Day's High
$14.20
$14.20
Day's Low
$14.00
$14.00
Volume
26,736
26,736
Avg. Vol
93,902
93,902
52-wk High
$16.29
$16.29
52-wk Low
$9.13
$9.13
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Charles Sherwood |
65 | 2002 | President, Chief Executive Officer, Director |
Sylvia Cheung |
2013 | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer, Secretary | |
Frank Luppino |
43 | 2009 | Chief Operating Officer |
William Mrachek |
2008 | Vice President - Human Resources | |
Joseph Bower |
74 | 2005 | Lead Independent Director |
Raymond Land |
67 | 2006 | Independent Director |
John Moran |
59 | 2006 | Independent Director |
Jeffery Thompson |
46 | 2011 | Independent Director |
Steven Wheeler |
65 | 1993 | Independent Director |
Biographies
| Name | Description |
|---|---|
Charles Sherwood |
Dr. Charles H. Sherwood is President, Chief Executive Officer, Director of Anika Therapeutics, Inc. Dr. Sherwood was appointed Chief Executive Officer of Anika Therapeutics in March 2002. Dr. Sherwood has served as President since June 2001. Dr. Sherwood previously served as Anika Therapeutics’ Chief Operating Officer beginning in June 2001, Vice President of Research and Development beginning in April 2000 and Vice President of Process Development and Engineering beginning in April 1998. Dr. Sherwood served as a consultant to Anika Therapeutics from January 1998 to April 1998. From 1995 to 1997, Dr. Sherwood was Senior Director of Medical Device Research and Development for Chiron Vision. In April 1995, Chiron Vision acquired IOLAB Corporation, a division of Johnson & Johnson where Dr. Sherwood had been Executive Director of Research and Development from 1993 to 1995, Director of Materials Characterization from 1989 to 1993 and Manager/Section Head from 1982 to 1989. Dr. Sherwood was also a part-time faculty member in the Department of Chemistry at the California State Polytechnic University, Pomona, California from 1984 to 1987. Dr. Sherwood received a B.S. in Chemical Engineering from Cornell University, and an M.S. and Ph.D. in Polymer Science and Engineering from the University of Massachusetts, Amherst. Dr. Sherwood also received a Certificate in Management from Claremont Graduate School. |
Sylvia Cheung |
Ms. Sylvia Cheung has been appointed as the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer, Secretary of Anika Therapeutics, Inc., effective April 1, 2013. Ms. Cheung has over 16 years of financial and general management experience. Prior to her current position as Vice President of Strategic Processes, Cheung served as General Manager for the company’s Italy-based subsidiary, Anika Srl. She joined Anika as Controller in 2005. In addition to fulfilling financial responsibilities as Controller, Cheung led the company’s integration of Anika Srl subsequent to its acquisition in 2009. Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. Cheung holds a bachelor’s of business administration in accounting from the University of Massachusetts in Amherst, a master’s in business administration from Boston University, and is a Certified Public Accountant (inactive). |
Frank Luppino |
Mr. Frank J. Luppino is Chief Operating Officer of Anika Therapeutics, Inc., since May 2009. Previously, Mr. Luppino served as Vice President of Operations at Bionostics from 2007 to 2009. From 2003 to 2007, he served as Anika's Vice President of Operations. Mr. Luppino began his Anika career in 1999, and held several positions of increasing responsibility in the operations area. Prior to Anika, Mr. Luppino was Regional Manager for AAC Consulting Group, a firm serving the pharmaceutical and medical device industries. From 1992 to 1998, he was Regional Manager for Raytheon Engineers and Constructors. Mr. Luppino holds a BS degree in chemical engineering from Lehigh University. |
William Mrachek |
Mr. William J. Mrachek was Vice President - Human Resources of Anika Therapeutics, Inc. In 2008 was promoted to Vice President of Human Resources after serving as the Executive Director of Human Resources since 2003. Previously, Mr. Mrachek served as the Vice President of Human Resources for iQ NetSolutions, a start-up engaged in the proprietary Enterprise telephony solutions converging both voice and data. From 1994 to 2000, Mr. Mrachek was Director of Human Resources for Programart Corp in Cambridge, MA, a private software company developing application performance management products for the mainframe market. Previously, Mr. Mrachek served as Vice President of Human Resources for SofTech, Inc., a public company located in Waltham, MA, engaged in selling software development and engineering services primarily for the Federal government as well as the product reselling of computers, network equipment, and packaged software. Mr. Mrachek holds a BA degree from Colorado College, a MBA from the University of Denver, and a JD from the University of Colorado School of Law. He serves on the Board of Directors for the Faulkner Hospital in Boston. |
Joseph Bower |
Dr. Prof. Joseph L. Bower is Lead Independent Director of Anika Therapeutics, Inc. He joined the Board of Directors of Anika Therapeutics in February 1993 and has served as lead director since April 2005. Since 2008, he has been the Baker Foundation Professor of Business Administration at Harvard Business School, and prior to 2008, he was the Donald Kirk David Professor of Business Administration. Dr. Bower serves as a director of Loews Inc., the New America High Income Fund and Sonesta International Hotels Corporation. During the past five years, Dr. Bower served as a director of the TH Lee Putnam EOP Fund. Dr. Bower brings to the Board more than three decades of experience in corporate governance and management, during which he has written books and taught these subjects at the Harvard Business School. Additionally, he has consulted with numerous organizations on problems of strategy and organizational development, including strategic planning and succession planning. |
Raymond Land |
Mr. Raymond J. Land is an Independent Director of Anika Therapeutics, Inc., since January 2006. He serves as Chairman of the Board of BioAmber, Inc., a privately held company developing chemicals from renewable feedstocks, and a Director and Chairman of the Audit Committee of Mountain View Pharmaceuticals, Inc., a privately held company specializing in biopharmaceuticals. In 2010, Mr. Land retired as the Senior Vice President and Chief Financial Officer of Clarient, Inc. (CLRT), an advanced molecular diagnostics company. From June 2007 to May 2008, he was the Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc. (SFE), a venture capital firm. Prior to Safeguard Scientifics, Inc., Mr. Land held executive management and chief financial officer positions at Medcenter Solutions, Inc., a global pharmaceutical marketing company where he was also a Board member and Orchid Cellmark (ORCH), a provider of identity of DNA testing services. Mr. Land previously served as Senior Vice President and Chief Financial Officer for Genencor International, Inc., (GCOR), a diversified biotechnology company focusing on bioproducts and healthcare from 1997 until its acquisition in April 2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for West Pharmaceutical Services, Inc. (WST). Previously, Mr. Land was with Campbell Soup Company, Inc. (CPB) where for nine years he held increasingly senior financial positions and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, he was with Coopers and Lybrand for nine years. Mr. Land is a Certified Public Accountant and has a degree in accounting and finance from Temple University. |
John Moran |
Mr. John C. Moran is an Independent Director of Anika Therapeutics, Inc., since December 2006. In 2009, Mr. Moran became the President, CEO and Chairman of Core Essence Orthopaedics. From 1997 to 2009, he was a private investor in a number of companies, mostly in the medical devices field. From 1990 to 1997, Mr. Moran served as the first President of Synthes Spine, a division of Synthes (USA), the skeletal fixation company in the world. Synthes Spine designs, manufactures and distributes implants and instruments for spinal disorders. During Mr. Moran’s six-year tenure as President of Synthes Spine, sales grew from less than $1 million to more than $60 million annually. Mr. Moran serves as a director of Paradigm Spine LLC, Rainer Technologies, and is Chairman of the Board of Core Essence Orthopaedics. Mr. Moran received a Bachelor’s Degree from the University of Notre Dame, and holds a Master’s degree in business administration from the Harvard Business School. |
Jeffery Thompson |
Mr. Jeffery S. Thompson is an Independent Director of Anika Therapeutics Inc., since January 2011. He is an Operating Partner for HealthEdge Investment Partners, LLC (“HealthEdge”), a Tampa, Florida based private equity firm that provides strategic capital exclusively in the healthcare industry. Mr. Thompson serves as President, CEO, and Chairman of Advanced Bio-Technologies, Inc. and as Chairman of Woodbury Products, Inc., both HealthEdge portfolio companies. Prior to joining HealthEdge, he served as Chief Operating Officer for Stiefel Laboratories, Inc., the world’s independent pharmaceutical company specializing in dermatology. Prior to his COO role, he was Stiefel’s Senior Vice President U.S. Business Services and President of Glades Pharmaceuticals. Earlier in his career, Mr. Thompson held sales and business management positions at Bausch & Lomb Pharmaceuticals and SmithKline Beecham. Mr. Thompson is a graduate of the University of Pittsburgh. |
Steven Wheeler |
Mr. Steven E. Wheeler is an Independent Director of Anika Therapeutics, Inc., since February 1993. He is President of Wheeler & Co., a private investment firm. He is a Director of Bariston Partners LLC, PingTone Communications, Inc. and HFF, Inc. Between 1993 and 1996, he was Managing Director and a Director of Copley Real Estate Advisors and President, Chief Executive Officer and a Director of Copley Properties, Inc., a publicly traded real estate investment trust. From 1991 to 1993, he was Chairman and Chief Executive Officer of Hancock Realty Investors, which manages an equity real estate portfolio. Earlier, he was an Executive Vice President of Bank of New England Corporation from 1990 to 1991. Mr. Wheeler received a Bachelor’s Degree in engineering from the University of Virginia, a Master’s Degree in nuclear engineering from the University of Michigan and a Master’s Degree in business administration from the Harvard Business School. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Charles Sherwood |
1,479,960 |
Sylvia Cheung |
-- |
Frank Luppino |
778,693 |
William Mrachek |
330,955 |
Joseph Bower |
-- |
Raymond Land |
-- |
John Moran |
-- |
Jeffery Thompson |
-- |
Steven Wheeler |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Charles Sherwood |
712,500 | 5,198,900 |
Sylvia Cheung |
0 | 0 |
Frank Luppino |
271,750 | 1,530,689 |
William Mrachek |
0 | 0 |
Joseph Bower |
0 | 0 |
Raymond Land |
0 | 0 |
John Moran |
0 | 0 |
Jeffery Thompson |
0 | 0 |
Steven Wheeler |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
QUINLAN KEVIN W |
18,374 | $11.24 |
QUINLAN KEVIN W |
18,374 | $11.24 |
QUINLAN KEVIN W |
19,998 | $11.24 |
QUINLAN KEVIN W |
11,628 | $11.24 |
QUINLAN KEVIN W |
19,998 | $11.24 |
QUINLAN KEVIN W |
11,628 | $11.24 |
QUINLAN KEVIN W |
25,000 | $11.24 |
QUINLAN KEVIN W |
25,000 | $11.24 |
LAND RAYMOND J |
950 | $14.00 |
LAND RAYMOND J |
325 | $14.00 |
LAND RAYMOND J |
925 | $14.00 |
QUINLAN KEVIN W |
6,368 | $6.99 |
QUINLAN KEVIN W |
5,000 | $6.99 |
BOWER JOSEPH L |
2,760 | $0.00 |
LAND RAYMOND J |
2,760 | $0.00 |
THOMPSON JEFFERY S |
2,760 | $0.00 |
MORAN JOHN C |
2,760 | $0.00 |
WHEELER STEVEN E |
2,760 | $0.00 |
BOWER JOSEPH L |
100,000 | $0.00 |
SHERWOOD CHARLES H |
17,127 | $1.05 |
SHERWOOD CHARLES H |
22,873 | $1.05 |
LUPPINO FRANCESCO J |
5,979 | $5.01 |
LAND RAYMOND J |
1,500 | $11.92 |
LAND RAYMOND J |
1,000 | $12.13 |
SHERWOOD CHARLES H |
20,000 | $12.15 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
